L3VLUP
ProSign in

NTRA · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NTRAVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NTRA
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNTRAVRTX
Q3 202016 holders, $575m31 holders, $21.9bn
Q4 202015 holders, $741m30 holders, $18.4bn
Q1 202117 holders, $911m31 holders, $15.4bn
Q2 202120 holders, $1.4bn30 holders, $12.7bn
Q3 202117 holders, $1.3bn35 holders, $10.1bn
Q4 202114 holders, $1.2bn28 holders, $12.4bn
Q1 202213 holders, $551m23 holders, $16.1bn
Q2 202214 holders, $473m25 holders, $18.1bn
Q3 202210 holders, $365m22 holders, $18.4bn
Q4 202212 holders, $266m28 holders, $18.4bn
Q1 202314 holders, $658m26 holders, $21.4bn
Q2 202310 holders, $474m27 holders, $24.7bn
Q3 202310 holders, $554m33 holders, $24.3bn
Q4 202312 holders, $695m32 holders, $28.6bn
Q1 202418 holders, $2.0bn31 holders, $29.8bn
Q2 202422 holders, $2.5bn29 holders, $33.4bn
Q3 202425 holders, $3.6bn27 holders, $33.5bn
Q4 202428 holders, $4.5bn26 holders, $28.5bn
Q1 202521 holders, $4.6bn21 holders, $35.4bn
Q2 202521 holders, $5.4bn21 holders, $32.3bn
Q3 202523 holders, $4.8bn22 holders, $25.9bn
Q4 202526 holders, $8.1bn26 holders, $31.8bn
Q1 202620 holders, $6.7bn25 holders, $31.8bn
Q2 202623 holders, $10.0bn26 holders, $34.6bn
NTRA

Natera Inc

Holders
23
Reported value
$4.8bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NTRA (16)

AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Coatue Management LLC, Farallon Capital Management LLC, Holocene Advisors LP, Maverick Capital Ltd, PDT Partners LLC, Point72 Asset Management LP, Polen Capital Management LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Winton Group Ltd

Only VRTX (15)

AllianceBernstein LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, Tudor Investment Corp, Voloridge Investment Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →